ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...

While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Despite their potential, RNA-based therapies are faced with major challenges: The instability of RNA and its rapid degradation in the body, combined with the necessity of ultra-cold storage or ...

2018 saw a breakthrough in the field of RNA interference (RNAi), when the US FDA approved the first drug using this gene-silencing mechanism. Five years and five more approved drugs later ...

After hours: February 14 at 6:27:18 PM EST Loading Chart for RNA ...

RNA (ribonucleic acid) is a nucleic acid polymer where the carbohydrate is ribose. RNA is generally single-stranded, as DNA is transcribed by RNA polymerases into mRNA (messenger RNA), which is ...

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra ...

Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled ...